Carisma Therapeutics Set to Shine at SITC 2024
Carisma Therapeutics, a clinical-stage biopharmaceutical company, is gearing up to make waves at the upcoming Society for Immunotherapy of Cancer (SITC) event in Houston, Texas this November. The company announced its participation in the event and the unveiling of poster presentations that promise innovation and potential breakthroughs in the field of immunotherapies.
Highlighted Presentations
Carisma Therapeutics will be showcasing two key presentations at SITC 2024, each shedding light on cutting-edge research and development efforts aimed at revolutionizing cancer treatment:
- Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma.
- Publication Number: 329
- Session Date & Time: Friday, Nov. 8, 2024
- Location: Exhibit Halls A B George R. Brown Convention Center
- Title: A Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors.
- Publication Number: 659
- Session Date & Time: Friday, Nov. 8, 2024
- Location: Exhibit Halls A B George R. Brown Convention Center
Looking Forward
Following the presentations at SITC 2024, the posters will be accessible online on Carisma’s website, offering an opportunity for a wider audience to delve into the details of the groundbreaking work undertaken by the company.
About Carisma Therapeutics
Carisma Therapeutics Inc. is at the forefront of developing innovative immunotherapies to combat cancer and other severe ailments. Their focus on engineered macrophages and monocytes represents a pioneering approach to leveraging the body’s immune response for therapeutic benefits. With headquarters in Philadelphia, PA, Carisma is dedicated to pushing the boundaries of medical science to create a healthier future.
Embracing the Future
As Carisma Therapeutics prepares to showcase its cutting-edge research at SITC 2024, investors and industry experts eagerly await the potential insights and advancements that could emerge from these presentations. The company’s commitment to transforming the landscape of immunotherapies underscores a dedication to innovation and excellence.
The Future Unveiled: Carisma Therapeutics’ Anticipated Presentations
Exploring Potential Risks and Uncertainties
Carisma Therapeutics, a key player in the realm of biopharmaceuticals, is set to divulge insights at the upcoming Society for Immunotherapy of Cancer (SITC) 2024 conference. This scientific event is poised to shed light on Carisma’s strategic advancements and future trajectory, enticing investors and stakeholders alike.
Steering Clear of Hazards
To understand the full spectrum of risks and uncertainties surrounding Carisma Therapeutics, a thorough examination of the company’s Annual Report on Form 10-K for the year ending December 31, 2023, and its Quarterly Report on Form 10-Q for the quarter closing on June 30, 2024, is advised. These filings serve as crucial compasses in navigating the turbulent waters of the biopharmaceutical landscape.
Staying Informed at Every Turn
Carisma Therapeutics, in line with regulatory standards, keeps its investor community abreast of potential risks, uncertainties, and other pivotal factors through regular filings with the Securities and Exchange Commission. This transparency underscores the company’s commitment to open communication and adherence to regulatory frameworks.
Directing Attention to the Present
While looking forward to enlightening audiences with forward-looking statements at the SITC 2024 conference, Carisma Therapeutics emphasizes that any such statements made in the present speak solely to the date of the announcement. The company vows to uphold a policy of timely updates, ensuring accuracy and relevancy for its stakeholders.
Engagement Opportunities
For investors curious about Carisma Therapeutics and its strategic vision, Shveta Dighe, the Head of Investor Relations, stands ready to offer insights and guidance. Investors can reach out directly to investors@carismatx.com to delve deeper into the company’s financial performance and prospects.
Media Inquiries Welcomed
For media-related queries or interviews, Julia Stern, a key figure at Carisma Therapeutics, awaits at (763) 350-5223 or through email at jstern@realchemistry.com. Media professionals seeking in-depth information or commentary can directly engage with the company through Julia Stern’s contact information.
Staying Connected
To stay informed about the latest updates and developments from Carisma Therapeutics, interested parties can refer to the original content published by the company. By following the sources provided, stakeholders can access first-hand information, fostering a deeper understanding of Carisma’s journey and milestones.
